By Joey Wong, Senior Investor Research Analyst, Hong Kong BD, LSN
RESI South is rapidly approaching, taking place in person on March 25 in Atlanta at The Whitley Buckhead Hotel, followed by two days of virtual partnering on March 26-27. For this highly anticipated conference, LSN’s Investor Research Team has curated a lineup of 7 panels covering a wide range of topics relevant to early-stage investments and innovations.
At RESI South, we have a series of panels that feature key players in the startup investment ecosystem, including Corporate Venture Capital and Seed Funds. The panelists will delve into their investment and partnership strategies, how they evaluate prospects, manage relationships with their early-stage portfolio, and their unique position in the ecosystem, among other topics.
Other panels will focus on emerging sectors that have been gaining interest and momentum, such as Digital Health, AI in Healthcare, CNS Diseases, Longevity, and Chronic Disease Management. These panels will feature investors who have been actively following and allocating in these respective verticals. They will provide insights into cutting-edge innovations, the latest investment trends, the importance of these technologies, and how these markets will evolve in the future.
We are honored to be joined by a diverse group of panelists, each bringing unique backgrounds and experiences. Through organizing these panels, our goal is to foster communications, bridge the gap between entrepreneurs and investors/strategic partners, and assist founders and CEOs in navigating their fundraising and business development journey in this highly competitive landscape. Don’t miss the opportunity to hear from and connect with seasoned investors and executives at these RESI panels.
Here are the speakers for RESI South 2024:
 Peter Alff Senior Venture Partner Orange Grove Bio |
 Irene Blat Sr. Dir. Search & Evaluation, Oncology Servier |
 Natasha Bonett DeLong Portfolio Manager Rex Health Ventures |
 Mark Bouzyk President & CSO AllaiHealth |
 Justin Burns Vice President, Venture Development GRA Venture Fund, LLC |
 Rowan Cade Program Manager, BARDA Ventures Division of Research Innovation and Ventures (DRIVe) |
 Tom Callaway Founder Life Science Partner |
 Nicolas Cindric Partner Yahara Ventures |
 Drew Cutshaw Senior Associate & Medical Officer Pappas Capital |
 Sinclair Dunlop Managing Partner Epidarex Capital |
 Martin Gershon Managing Partner and CIO Endeavor Venture Funds, Senior Executive Investor-in-Residence Techstars |
 Deborah Hemingway Managing Partner Ecphora Capital |
 Ray Jang Principal Primetime Partners |
 Jennifer Jordan Venture Partner iGlobe Partners |
 Nancy Torres Kaufman CEO Beacon Capital LLC |
 Sarah Kleinpeter Global Vice President Alzheimer’s Disease Novo Nordisk |
 Jason Kuo Senior Associate & Lead Healthcare Investor Tech Square Ventures |
 Mankit Law Director, Worldwide Business Development GlaxoSmithKline (GSK) |
 Michelle (Waye) Leeuwon Program Manager for Product Development Cancer Prevention and Research Institute of Texas (CPRIT) |
 Ron Levin Managing Partner Alumni Ventures |
 Andy Merken Partner, Corporate & Securities Co-Chair, Life Sciences Burns & Levinson |
 Ross O’Brien Founder & Managing Partner Bonaventure Equity, LLC (BVE) |
 Allyson Plosko Partner SpringTime Ventures |
 William Plumer Managing Partner Bullet Partners |
 Preetha Ram Managing Partner Pier 70 Ventures |
 Thomas Saylor Chief Executive Officer, Serial Enterpreneur NeuroAcoustics |
 Katerina Stroponiati Co-Founding Partner Monday Capital |
 Nathan Styles Executive Director of McQuade Center for Strategic R&D Otsuka Pharmaceutical |
 Jim Tobin VP, Cardiovascular & Metabolism Scientific Innovation Johnson & Johnson Innovation |
 Liz Todia Principal Mutual Capital Partners |
 Robert Tucci Managing Director Texas HALO Fund |
 Dave Vreeland Senior Managing Partner Caduceus Capital Partners |
Next Phase Newsletter 
Leave a comment